Furthermore, high‐level amplifications targeting cancer‐critical genes, including the therapeutic targets ERBB2 and EGFR, were also typically homogeneously present within patients, both among multiple metastatic lesions and in the primary tumor. The gene discussed is EGFR; the disease is cancer.